Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
ATLANTA, Sept. 01, 2016 -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, September 8, 2016 at 4:30 p.m. ET to review the Company’s financial results for the three month period and 2016 fiscal year ended June 30, 2016 and will provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call.
In order to participate in the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122 (international) and refer to conference ID number 74878442. The live webcast can be accessed under the Investors section of the Company’s website at www.aviragentherapeutics.com.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: vapendavir, an oral treatment for human rhinovirus upper (HRV) respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
